The Senate Caucus on International Narcotics Control was established in 1985 and is a standing committee of the Senate. The caucus’ seven bipartisan members work to combat international narcotics trafficking and reduce domestic drug abuse.
As Co-chairman, Senator Feinstein is particularly interested in U.S. efforts to reduce drug trafficking and drug-related violence in Mexico and Afghanistan, as well as to more effectively address the opioid and drug overdose crisis that has gripped our nation.
As it relates to international narcotics, the Caucus has held hearings on strategies to dismantle Mexican drug trafficking organizations, money laundering, the proliferation of border tunnels along the Southwest border, the Taliban’s drug trafficking operations in Afghanistan and the trafficking of clandestinely produced fentanyl that is ultimately destined for the United States.
On the domestic side, the Caucus has held hearings on how to best stop methamphetamine production and abuse, the dangers of new and emerging drug trends that threaten public health and safety, including opioids, fentanyl, and other synthetic drugs such as K2, Spice and bath salts.
As a result of her work on the Caucus, Senator Feinstein has been responsible the passage of a number of important pieces of legislation, including but not limited to the following:
- The Transnational Drug Trafficking Act (P.L. 114-154). This bill allows for the prosecution of drug traffickers if there is a “reasonable cause to believe” that the drugs they are shipping will be trafficked into the United States. It also imposes penalties on individuals who manufacture or distribute precursor chemicals knowing that the chemicals will be used to make illicit drugs destined for the United States.
- Two Border Prevention Tunneling Acts, which criminalize the financing and construction of cross-border tunnels. For more information on these bills, which were enacted in 2006 (P.L. 109-295) and 2012 (P.L. 109-295) click here.
- Using Data to Prevent Opioid Diversion Act (P.L. 115-271). - This bill holds drug manufacturers and distributors accountable for failure to report suspicious orders of opioids, and was included in the comprehensive opioid package that was signed into law in 2018.
- The SUPPORT Act (P.L. 115-271). In addition to the Using Data to Prevent Opioid Diversion Act, Senator Feinstein co-authored a number of other key provisions in the opioid package, known as the SUPPORT Act, including provisions to reauthorize the Office of National Drug Control Policy and other critical substance abuse prevention, treatment, and enforcement programs that directly benefit California, such as the Drug Free Communities, High Intensity Drug Trafficking Areas and drug court programs.
Co-chairman Feinstein has authored a number of reports with her colleagues on how best to reduce the trafficking of illegal drugs and drug-related violence. Below is a list of recent reports the caucus has released:
The complete list of reports issued by the Caucus, as well as a calendar of future and past Caucus hearings are available on the Drug Caucus website.
Related Press Release
|2/5/15||Feinstein, Hatch Introduce Bill to Combat Damage from Marijuana Grows|
|1/6/15||Feinstein, Portman Introduce Bill to Crack Down on Synthetic Drugs|
|12/15/14||Feinstein, Grassley Bill to Combat Transnational Drug Trafficking Passes Senate|
|9/22/14||Senators Urge White House to Request Resources on Antibiotic Resistance|
|8/22/14||Feinstein Applauds Reclassification of Drugs Containing Hydrocodone|
|6/24/14||Grassley, Feinstein Explore Medicare Surveys and Opioid Abuse Link|
|1/16/14||Feinstein Statement on Future of Counternarcotics Efforts in Afghanistan|